Yatharth Hospital Reports Q2 Profit Rise and Strategic Advent Deal

Revenue grew to INR 4,314.20 million in Q2FY27 from INR 2,830.14 million in Q2FY25. Net profit rose to INR 505.87 million from INR 412.02 million in the same quarter last year.

Reader Takeaway: Strong operational momentum driven by 52% revenue growth, offset by significant pending tax litigation risk across subsidiaries.

What just happened

Yatharth Hospital & Trauma Care Services has reported its financial results for the quarter ended September 30, 2026. Simultaneously, the company confirmed it has moved forward with a definitive agreement for Rasmalai Limited, an affiliate of private equity major Advent International, to acquire a 24.9% equity stake. Shareholders have already greenlit this transaction during an EGM held on October 15, 2026.

Why this matters

The strategic entry of Advent International is a significant vote of confidence in the hospital chain’s expansion model. Financially, the 52% year-on-year jump in operating revenue highlights robust demand across its network. However, the shadow of substantial income tax assessment orders—totaling over INR 650 million in principal and interest—creates a layer of uncertainty. The company has not provisioned for these demands, asserting that it expects significant relief through the appeal process.

Risks to watch

The primary risk is the ongoing income tax litigation. The demands cover assessment years from 2014-15 to 2024-25 across the parent company and its subsidiaries, AKS Medical & Research Centre and Ramraja Multispeciality Hospital. Investors should watch for the outcomes of these appeals at the CIT (Appeals) level. Additionally, the Advent deal remains subject to various regulatory clearances and customary closing conditions.

What to track next

Monitor for updates on regulatory approvals for the stake sale and any procedural developments in the tax appeals. The company also recently issued 227,693 employee stock options, signaling ongoing human capital investment.